FDA Clearance Tracker · P130006-S091
GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
Last checked: Nov 20, 2026Latest source record: May 26, 2022 (this decision)Source: openFDAMethods & limitations
Decided
May 26, 2022
Approved
Time to decision
101 days
Received Feb 14, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P130006-S091
- Device name
- GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
- Applicant
- W. L. Gore & Associates, Inc.
- Applicant location
- Flagstaff, AZ
- Received
- Feb 14, 2022
- Decided
- May 26, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P130006
Device type
- Device type
- System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the post-approval labeling update to include the final results of the RELINE MAX New Enrollment Study (ISR 04-04)
Source documents
Other decisions for W. L. Gore & Associates, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- GORE® VIABAHN® VBX Balloon Expandable EndoprosthesisPMA supplement
P160021-S051 · Decided Oct 8, 2026 · 244 days after receipt · Panel Track
Device type: Iliac covered stent, arterial (PRL) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.